POPART – A PedCRIN Funded Trial For Preterm Infants, Recruiting in Ireland
PedCRIN brings together the European Clinical Research Infrastructure Network (ECRIN) and the founding partners of the European Paediatric Clinical Trial Research Infrastructure (EPCT-RI) and is funded by the European Union’s Horizon 2020 programme. PedCRIN was founded in response to the widely acknowledged difficulties in conducting investigator-led trials of investigational medicinal products in children.
Applications were sought for funding to support trials that would be conducted in Europe. The POPART team, led by Principal Investigator Prof. Colm O’Donnell (Consultant Neonatologist, National Maternity Hospital and UCD), was one of 3 successful applicants, obtaining funding (€430,000) from PedCRIN to support the POPART (Prophylactic Oropharyngeal Surfactant for Preterm infant: A Randomised Trial) trial, which asks the question:
- (P) Among infants born before 29 weeks of gestation
- Does prophylactic oropharyngeal surfactant
- (C) Compared to no intervention
- (O) Reduce the rate of endotracheal intubation for respiratory failure
- (T) Within 120 hours of birth?
This trial will enroll 250 infants in several European countries (Ireland, Sweden, Norway, Denmark, Czech Republic, Italy, Portugal). Recruitment started at the National Maternity Hospital in Dublin in mid December 2017 and 5 babies have been enrolled to date.
The trial is sponsored by UCD and forms the central part of Dr. Madeleine Murphy’s research that she will submit for the degree of PhD at UCD. Madeleine is very kindly supported by a clinical research fellowship from the National Children’s Research Centre.
This award is good news for clinical research in Ireland in general; and for clinical research in paediatrics in Ireland in particular.
Read a further summary of the POPART trial here.